GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cambium Bio CMB.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.36

-10.00%

Close of 4 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Cambium Bio — daily ASX:CMB

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Cambium Bio on TradingView ↗
Market value
A$8.3m
Last close × shares
Volume
515
Shares, 4 Nov 2026

About Cambium Bio

Its shares trade on ASX under the ticker CMB.AX. It has been listed since 19 September 2013. In the fiscal year to 30 June 2026, it reported revenue of A$641,638 and a net loss of A$4.1m. At that date it held total assets of A$3.8m and shareholders' equity of A$2.4m.

Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.

Figures and description from our data supplier, not checked against the company's own report.

More about Cambium Bio →

Latest on Cambium Bio

Our reporting

We have not reported on Cambium Bio yet.

Next results

4 Mar 2027

Due on 4 Mar 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Cambium Bio's ticker?

Cambium Bio trades as CMB.AX on ASX, under ISIN AU0000327769.

What was Cambium Bio's last closing price?

0.36 on 4 Nov 2026. The figure is in AUD and is never converted.

When does Cambium Bio next report results?

Results are expected on 4 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.